Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04157985 · ClinicalTrials.gov registry record · Phase 3
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
A Phase 3 study of Colorectal Cancer and Melanoma, sponsored by Dan Zandberg.
- Completed
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
- 1
- Study location
NCT04157985 is a Phase 3 study of Colorectal Cancer and Melanoma that has completed, run by Dan Zandberg. The registered enrollment target is 161 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04157985, a Phase 3 study of Colorectal Cancer and Melanoma, has completed, sponsored by Dan Zandberg.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.
Conditions Studied
Interventions
- DRUG Continue PD-1/PD-L1 Inhibitors treatment
- OTHER Discontinue PD-1/PD-L1-1 inhibitor
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2025-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04157985
The ClinicalTrials.gov registry entry for NCT04157985 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Dan Zandberg, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Continue PD-1/PD-L1 Inhibitors treatment is the first listed.
NCT04157985 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04157985 about?
NCT04157985 is a clinical study titled "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors". Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment unti...
What is the current status of trial NCT04157985?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2019-11-15. Estimated completion is 2025-11-07.
What conditions does trial NCT04157985 study?
This clinical trial studies the following conditions: Colorectal Cancer, Melanoma, Bladder Cancer, Gastric Cancer, Advanced Solid Tumors.
What interventions are being tested in trial NCT04157985?
The interventions under investigation include: Continue PD-1/PD-L1 Inhibitors treatment (DRUG), Discontinue PD-1/PD-L1-1 inhibitor (OTHER).
Who is sponsoring clinical trial NCT04157985?
This trial is sponsored by Dan Zandberg, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04157985 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
The Northern-European Initiative on Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
COMPLETED · Phase 3
-
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 3
-
Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer
COMPLETED · Phase 3
-
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.